Absci partners with AMD, investing $20 million to enhance AI-driven drug discovery and antibody design capabilities. Quiver AI Summary. Absci Corporation has announced a strategic partnership with ...

--Absci Corporation, a data-first generative AI drug creation company, today announced a strategic collaboration with AMD to deploy AMD Instinct™ accelerators and ROCm™ software to power ...

AMD’s support will enable Absci to enhance its proprietary antibody design model, IgDesign1, which is the first in vitro validated inverse folding model for antibody design.

Summary. Absci recently received a $20 million PIPE investment from AMD that improves its runway and R&D platform with AI. ABS-101 appears to be ABSI’s main drug candidate for IBD.

Absci is also working with AMD to develop hardware and software that will better serve the healthcare sector and AI-based drug discovery work, he added. The company has about 160 employees and has ...

$20 Million Equity Investment from AMD Strengthens Absci’s Leadership in AI Drug Discovery and Further Expands Biopharma Adoption of AMD Instinct Accelerators and ROCm SoftwareVANCOUVER, Wash ...

AMD collaborates with Absci for AI drug discovery advancements. AMD makes a $20 million investment to boost drug research. Up Next: Get 5 Dark Horse Stocks Wall Street Is Quietly Loading Up On The ...

AMD Invests in Drug-Discovery Company Absci in Push to Sell AI Chips. The $20 million deal gives the chip supplier a toehold in the life-sciences market, ...

VANCOUVER, Wash., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration with AMD to deploy AMD ...

VANCOUVER, Wash., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (ABSI) (NASDAQ: ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration with AMD to ...